// App-Quantinova.ai

: Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra

Researchers

Presenter

  • Ingmar Bruns

Principal Investigators

  • Mary Fitzgerald

  • Katerina Pardali

  • Gardiner Philip

  • Keeling David

  • Axelsson Lena

  • Jiang Fanyi

  • Lickliter Jason

  • Close David

Medical Centers

  • Pieris Pharmaceuticals, Boston, United States of America

  • Respiratory, Inflammation and Autoimmunity iMed, AstraZeneca, Gothenburg, Sweden,

  • Respiratory, Inflammation and Autoimmunity, Early Clinical Development, AstraZeneca, Gotherburg, Sweden

  • Nucleus Network, Melbourne, Australia

  • Respiratory, Inflammation and Autoimmunity, Early Clinical Development, AstraZeneca, Gotherburg, Sweden

Locations

  • United States

  • Sweden

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • Phosphorylated signal transducer and activator of transcription 6

  • Interleukin 4

  • Signal Transducer And Activator Of Transcription 6

Drug/Treatment

  • Nitric oxide

  • PRS060

  • IL-4

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • First-In-Human

Phase

  • I

Study Id's

  • NCT03384290

  • NCT03574805

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved